Ejection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA

Similar documents
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)

Diastolic Heart Failure Uri Elkayam, MD

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Objectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009

HFpEF, Mito or Realidad?

HFpEF 2016 : Comorbidities and Outcomes

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)

What to do for the Patient with Heart Failure and Preserved Ejection Fraction: HFpEF

Heart Failure with preserved ejection fraction (HFpEF)

HF-PEF: Symptoms, quality of life and mortality/morbidity

Heart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre

HF-Preserved Ejection Fraction

Stable Angina: Indication for revascularization and best medical therapy

Therapeutic Targets and Interventions

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

HFpEF. April 26, 2018

Οξεία Καρδιακή Ανεπάρκεια: Κλινική εικόνα, ταξινόμηση κινδύνου & προγνωστικοί δείκτες

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Heart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.

The ACC Heart Failure Guidelines

Heart Failure in Women

Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy

Sleep Disordered Breathing and HH with Preserved Ejection Fraction:

Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides

Heart Failure A Disease for the Internist?

Diagnosis is it really Heart Failure?

Evidence of Baroreflex Activation Therapy s Mechanism of Action

Imaging in dilated cardiomyopathy : factors associated with a poor outcome

Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Preserved EF with heart failure (HF pef) 50% 5 year survival. Both have type 2 diabetes Both have hypertension Both have normal ejection fractions

Heart Failure Guidelines For your Daily Practice

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Vitals HR 90 BP 125/58 Tmax 98.7F O2 Sat 97% on NC 2L/min BMP SCr 1.78 K 3.9 Gluc 194 A1c 7.5 Cardiac LVEF 55% NTproBNP 9,200 Troponin 0.

Gender Differences in Comorbidities of Heart Failure Patients with Preserved or Reduced Left Ventricular Ejection Fraction

HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2

Congestive Heart Failure: Outpatient Management

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure

Transcatheter InterAtrial Shunt Device for the Treatment of Heart Failure: Results From the REDUCE LAP-HF I Randomized Controlled Trial

What the Cardiologist needs to know from Medical Images

THE PROPER APPROACH TO DIAGNOSING HEART FAILURE WITH PRESERVED EJECTION FRACTION

Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy

NT-proBNP: Evidence-based application in primary care

Chronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

HEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

«Paradoxical» low-flow, low-gradient AS with preserved LV function: A Silent Killer

Aldo P. Maggioni, Kees Van Gool, Nelly Biondi, Renato Urso, Niek Klazinga, Roberto Ferrari, Nikolaos Maniadakis and Luigi Tavazzi.

Heart Failure 101 The Basic Principles of Diagnosis & Management

Heart Failure with Preserved Ejection Fraction (HFpEF): Natural History and Contemporary Management

DECLARATION OF CONFLICT OF INTEREST

HFpEF: How to optimise management

Heart Failure Update. Bibiana Cujec MD May 2015

Could care really be personalized: Genes, biomarkers or just one size fits all? Aldo P Maggioni Florence, Italy

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

HFpEF: Pathophysiology & Treatment

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?

Systolic and Diastolic Dysfunction: Four Upcoming Challenges

Saudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group

Importance of CRT team for optimization of the results: a European point of view

Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa

Chronic. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Michael G. Shlipak, MD, MPH

Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.

Diastology State of The Art Assessment

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

SUPPLEMENTAL MATERIAL

Online Appendix (JACC )

Interesting EP Cases Catheter ablation to treat congestive heart failure (CHF)

Interest of PVO2 assesment in HFpEF patients

SGK 2016 Session: Postgraduate Course in Heart Failure Lausanne, 15. June 2016 Heart Failure Guidelines 2016

Bi-Ventricular pacing after the most recent studies

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

WHAT S NEW IN HEART FAILURE

Cardiovascular Imaging Stress Echo

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long

All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

New in Heart Failure SGK autumn session 2012

Assessment and Diagnosis of Heart Failure

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

Heart Failure with Preserved Ejection Fraction. April 4, 2018 Mike Muellerleile M.D.

HFPEF Echo with Strain vs. MRI T1 Mapping

Cardiovascular Diseases in CKD

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management

Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment

The Dark Side of the Moon: Heart Failure with Preserved Ejection Fraction

Chronic Primary Mitral Regurgitation

New CHF Patient in my Office: What Should I Do?

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Role of Ablation of AF and PVCs in the Management of Heart Failure

ICD Therapy. Disclaimers

Transcription:

Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA

Word of caution!!! Incomplete understanding of a disease process may lead to incorrect classification with potential serious consequences Rabies was classified as a psychiatric illness before discovery of germ theory Lung cancer and brain cancers were lumped in one group early last century

Heart Failure Taxonomy Acute vs. Chronic Left vs. Right De Novo ADHF vs. acute on top of chronic ADHF Systolic vs. diastolic HFpEF vs. HFrEF Etc..

HFpEF vs. HFrEF Issues with definition i.e. what is the cut off value that dichotomizes the two syndromes? 40% 45% 50% Are these two syndromes distinct or consist of multiple overlapping phenotypes?

EF cut off values in clinical trials for HFpEF Trial EF cut off I-PRESERVE 45% DIG-PEF > 45% CHARM-Preserved > 40% PEP-CHF 40%

EF cut off values in population-based studies and registries Some studies used 40% (1) Others used 45% (2) Others used 50% (3,4) Others excluded the group 40% - 50% (5,6) 1- Mangala A et al, Am J Cardiol 2013 2- Ho et al, Circ heart fail 2011;4:36-43 3- Owan et al, NEJM 2006;355:251-59 4- Chinali M et al, Coron Artery Dis 2010;21:137-43 5- Bhatia et al, NEJM 2006;355:360-69 6- Goldberg R et al, Am J Cardiol 2013;111:1324-29

Do HFpEF and HFrEF represent: distinct or overlapping multiple phenotypes?

Are HFpEF and HFrEF overlapping or distinct phenotypes? One way to answer this question is to examine carefully the two extreme groups EF < 40% EF > 45-50% If each of these groups constitute homogenous patient population in terms of Patient characteristics Prognosis Response to therapy Then, the bimodal model has a merit

Does HFrEF represent a single disease entity? Analysis from HF-ACTION trial Total of 2331 patients with chronic HF EF 35% Cluster analysis using 45 variables Ahmad et al, JACC 2014;64:1765-74

Cluster Cluster 1 Features Older Caucasian males, Ischemic CMP 68%, 39% NYHA III-IV. Highest rates of comorbidities Lowest median peak VO2 and highest biomarker levels Cluster 2 Cluster 3 Cluster 4 Youngest, median age= 49, females 38%, highest BMI (34) 90% non-ischemic CMP Highest prior hospitalization, lowest biomarker levels and second highest peak VO2 80% ischemic CMP, Highest burden of angina (97%) Highest rates of prior PCI and CABG Second lowest peak VO2 and second highest biomarker level Second highest rate of prior hospitalizations Highest percentage of Caucasians (77%) and females 39%. Median age 55 years, 90% non-ischemic CMP. Lowest rate of prior hospitalization Lowest rates of risk factors and comorbidities Highest peak VO2, second lowest biomarker levels

Outcomes

This study indicate that HFrEF syndrome comprises multiple phenotypes

Does HFPEF represent a single disease entity? 379 with HFpEF (EF > 50%) Detailed clinical, lab, ECG and echo phenotyping 67 continuous variables Several statistical learning algorithms including unbiased cluster analysis Shah et al, Circulation 2015;131:269-79

Outcomes Shah et al, Circulation 2015;131:269-79

This study indicate that HFpEF syndrome comprises multiple phenotypes

Acute heart failure with preserved vs. reduced ejection fraction: Insights from HEARTS Regitry

HEARTS Registry Enrolled 2609 consecutive patients hospitalized with ADHF 18 hospitals from Saudi Arabia Between October 2009 and December 2010 Follow up until January 2013

HFpEF/HFrEF: LV function in HEARTS was categorized into 4 different groups: Normal LV function= >50% Mild dysfunction= 40-50% Moderate dysfunction= 30-40% Severe dysfunction= <30%

Distribution of LV Function Grades 50% 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% 45.5% 24.2% 13% 12.8% normal mild moderate severe

Baseline characteristics according to LVEF group

What is the pattern of baseline characteristics distribution among the 4 groups?

Demographics

Mean age according to LV function Proportion of patients above 70 years 66 64 62 60 58 56 54 45% 40% 35% 30% 25% 20% 15% 10% 5% 0%

Proportion of female patients BMI 70% 60% 50% 40% 30% 20% 10% 0% 35 30 25 20 15 10 5 0

Medical History

HTN Atrial fibrillation 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 30% 25% 20% 15% 10% 5% 0%

History of IHD COPD 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 12% 10% 8% 6% 4% 2% 0%

Vital Signs

SBP DBP 160 140 120 100 80 60 40 20 0 78.0 77.0 76.0 75.0 74.0 73.0 72.0 71.0 70.0 69.0 68.0

Investigations

LBBB GFR 16% 14% 12% 10% 8% 6% 4% 2% 0% 70 60 50 40 30 20 10 0

In-Hospital Complications

Shock VT/VF requiring Tx 12.00% 10.00% 8.00% 6.00% 4.00% 2.00% 0.00% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0%

Heart Failure Phenotypic Continuum Normal EF Low HFpEF HFrEF

We used Fisher s linear discriminant analysis to assess how much overlap is there if in fact it exists Normal EF Low HFpEF HFrEF

Different models were explored based on Clinical, laboratory and ECG variables Two final models were selected First model included all variables except the noninvasive hemodynamic parameters Second model included only the non-invasive hemodynamic parameters (SBP, DBP, MBP, PP and PP/MBP)

Fisher s LDA using clinical and laboratory parameters

Fisher s LDA using non-invasive hemodynamic parameters

LDA function-based between-group distance Mild Moderate Severe Normal 0.56 1.17 1.65 Mild 0.62 1.1 Moderate 0.48

Conclusion from HEARTS Registry Our data indicates that HF patient population comprises multiple overlapping phenotypes when phenotypically characterized according to EF strata The patient population with mild LV dysfunction (EF 40%-50%) seems to be closer to the group with EF>50%

Take-home Message HF taxonomy according to EF has significant limitations HF comprises multiple overlapping phenotypes when classified according to EF There are two groups at the two ends of the spectrum with in-between intermediate groups Each EF stratum consists of multiple phenotypes New taxonomy is needed to better classify and characterize HF patients

Thank you